Illumina Grows Clinical IVD Portfolio With Introduction Of NextSeq 550Dx And Expanded Use Of MiSeqDx

November 15, 2017

By Bio-IT World Staff

November 15, 2017 | Illumina announced today the introduction of its NextSeq 550Dx instrument, the company’s second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system. The company also announced that the intended use for the MiSeqDx instrument has been updated to include the use of DNA libraries generated from formalin-fixed paraffin embedded (FFPE) tissues, paving the way for clinical labs to use FFPE samples when developing clinical tests for new applications. With the NextSeq 550Dx and the MiSeqDx, Illumina now has a diagnostic NGS product portfolio capable of covering a broad range of clinical applications to serve almost any clinical lab need for NGS-based in vitro diagnostic (IVD) products.

NextSeq 550Dx

With dual boot functionality, the NextSeq 550Dx platform includes a diagnostic mode (Dx mode) and a research mode, which provides the flexibility to perform both clinical research and develop a range of IVD assays on a single instrument. For large clinical laboratories, the NextSeq 550Dx instrument offers a validated high-throughput platform and will soon provide access to an expanding pipeline of clinical applications in oncology and reproductive health.

Assays that are run on the NextSeq 550Dx instrument follow a simple process including sequencing and data analysis. The setup of workflows for different applications are fully integrated in NextSeq 550Dx software. The instrument also offers fully-integrated onboard analysis software with modular software architecture to support current and future assays.

“NGS is beginning to play a significant role in the clinic,” said Garret Hampton, Executive Vice President of Clinical Genomics at Illumina, in a press release. “Illumina is working to provide clinical solutions that support the diagnosis and management of complex diseases, as well as expanding the IVD menu.”

MiSeqDx

The expanded intended use of the MiSeqDx instrument enables the development of additional advanced diagnostic products and services at clinical labs by giving clinicians access to information generated on Illumina’s NGS technology. In addition to the updated intended use for the MiSeqDx system, Illumina also offers the regulated MiSeqDx Reagent Kit v3, the latest version of Illumina sequencing chemistry available to MiSeqDx customers, and the TruSeq Custom Amplicon Kit Dx for library preparation. These new products replace the MiSeqDx Universal Kit 1.0, which was regulated by the FDA in 2013 and allowed clinical labs to conduct DNA analysis using DNA obtained from human whole blood.

“The expansion and launch of these regulated platforms represent regulatory milestones important to the clinical community,” Kathy Davy, Vice President of Marketing, Clinical Genomics at Illumina, said in a written statement. “The most relevant genetic information that can help cancer patients is often contained in FFPE tissues removed during surgery. Information gleaned from these samples can inform clinicians about tumor biology and help guide therapeutic selection.”

Illumina has updated the existing intended use for the MiSeqDx system to include the use of FFPE sample inputs for assays performed on the instrument. This update will support the launch of the following new reagent kits:

  • TruSeq Custom Amplicon Kit Dx
  • TruSeq Custom Amplicon Dx – FFPE QC Kit
  • MiSeqDx Reagent Kit v3 (2x300)

The MiSeqDx now has the following IVD menu:

  • Cystic Fibrosis 139-Variant Assay
  • Cystic Fibrosis Sequencing Assay
  • Extended RAS Panel
  • Germline Variant Module
  • Somatic Variant Module